He also failed to say that Tilray has a DEL from Health Canada giving them full access to countries that implemented tighter restrictions but Tilray explained things clearly. Now compare how a 'straight up' CEO talks to shareholders compared to the former Purdue drug pusher now at Medipharm. No retail buyers, no institutional buyers, no revenue contracts and a stagnant stock price. Stand back, it's pretty pathetic and desperate for this CEO at Medipharm to repeat like a parrot that they have strong balance sheet but fails to mention stagnant revenue growth. My piggy bank has $13.95 in it, it's debt free and it also has a strong balance sheet. There are NO filings by Medipharm Labs at the FDA for the NDA, ANDA, and 505(b)2. Something doesn't add up.
NEW YORK and NEUMNSTER, Germany, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), a global leader in cannabis research, cultivation, production, and distribution, today provides an update on Germany’s milestone cannabis legalization and what it means for the future of cannabis in Europe and for Tilray.
As a global leader in the legalized medical and adult-use cannabis markets and a market leader in medical cannabis across Europe, with a leading market share in Germany, Tilray is bullish on the positive paradigm shift that the new German drug policy creates for the future of cannabis in Europe.
Irwin D. Simon, Tilray Brands’ Chairman and Chief Executive Officer, stated, “We see tremendous growth opportunities stemming from Germany’s landmark cannabis policy update. The new German medical market opportunity equates to about $3bn while the European opportunity, could represent a powerful growth market consisting of a potential $45bn medical market alone. Our presence in Europe allows Tilray to grow our brands globally from a base of over 700 million people in Europe, which is twice the population of the U.S.”